AstraZeneca Pharma India Limited (ASTRAZEN) fundamentals
AstraZeneca Pharma India Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as ASTRAZEN (ISIN INE203A01020). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What AstraZeneca Pharma India Limited does
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacturing, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Valuation and market data
| Last close | ₹6755.00 |
|---|---|
| Market capitalisation | ₹16,887 crore |
| Enterprise value | ₹16,574 crore |
| P/E (TTM) | 90.05 |
| Price to book | 19.35 |
| Price to sales (TTM) | 4.07 |
| Book value per share | ₹349.13 |
| Dividend yield | 53.29% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri May 04 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹2,304 crore | ₹252 crore | ₹188 crore | 75.01 |
| Mar 2025 | ₹1,757 crore | ₹156 crore | ₹116 crore | 46.30 |
| Mar 2024 | ₹1,330 crore | ₹220 crore | ₹162 crore | 64.60 |
| Mar 2023 | ₹1,029 crore | ₹134 crore | ₹99 crore | 39.70 |
| Mar 2022 | ₹820 crore | ₹83 crore | ₹62 crore | 24.60 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 75.0% |
|---|---|
| Foreign institutions (FII) | 2.7% |
| Mutual funds | 6.0% |
| Other domestic institutions | 0.1% |
| Retail and others | 16.2% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.